PBE holdings — Invesco Biotechnology & Genome ETF
Invesco Biotechnology & Genome ETF (PBE) held 33 positions with net assets of $282M as of July 31, 2026, according to its Form N-PORT report to the SEC. Its top 10 holdings make up 56.8% of the fund, led by Invesco Private Prime Fund, REGN, AMGN.
PBE top holdings
- Invesco Private Prime Fund — 12.89% ($36.3M)
- REGN Regeneron Pharmaceuticals, Inc. — 5.47% ($15.4M)
- AMGN Amgen Inc. — 5.22% ($14.7M)
- CDNA CareDx, Inc. — 5.04% ($14.2M)
- VRTX Vertex Pharmaceuticals Inc. — 4.99% ($14.1M)
- Invesco Private Government Fund — 4.97% ($14.0M)
- RPRX Royalty Pharma PLC — 4.94% ($13.9M)
- BIIB Biogen Inc. — 4.79% ($13.5M)
- GILD Gilead Sciences, Inc. — 4.43% ($12.5M)
- UTHR United Therapeutics Corp. — 4.08% ($11.5M)
- TECH Bio-Techne Corp. — 3.73% ($10.5M)
- ILMN Illumina, Inc. — 3.51% ($9.89M)
- PTGX Protagonist Therapeutics, Inc. — 3.40% ($9.57M)
- VCEL Vericel Corp. — 3.27% ($9.21M)
- ALNY Alnylam Pharmaceuticals, Inc. — 3.17% ($8.93M)
- INCY Incyte Corp. — 3.06% ($8.62M)
- RGEN Repligen Corp. — 3.04% ($8.57M)
- ACAD Acadia Pharmaceuticals Inc. — 3.02% ($8.52M)
- HALO Halozyme Therapeutics, Inc. — 2.98% ($8.41M)
- QGEN Qiagen N.V. — 2.89% ($8.16M)
- BMRN BioMarin Pharmaceutical Inc. — 2.82% ($7.95M)
- NBIX Neurocrine Biosciences, Inc. — 2.66% ($7.50M)
- EXEL Exelixis, Inc. — 2.64% ($7.43M)
- BCRX BioCryst Pharmaceuticals, Inc. — 2.63% ($7.43M)
- VCYT Veracyte, Inc. — 2.60% ($7.34M)
What are PBE's top 10 holdings?
Invesco Private Prime Fund (12.9%), REGN (5.5%), AMGN (5.2%), CDNA (5.0%), VRTX (5.0%), Invesco Private Government Fund (5.0%), RPRX (4.9%), BIIB (4.8%), GILD (4.4%), UTHR (4.1%).
How many stocks are in PBE?
Invesco Biotechnology & Genome ETF reported 33 holdings as of July 31, 2026.